Date: 2014-04-30
Type of information: R&D agreement
Compound:
Company: Genzyme (USA - MA), a Sanofi company (France) - Cleveland Clinic (USA - OH)
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
Type agreement:
Action mechanism:
Disease: multiple sclerosis
Details: * On April 30, 2014, Genzyme, a Sanofi company, has announced the formation of a research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of multiple sclerosis.This collaboration aligns the research efforts of both organizations around projects which are designed to develop a deep understanding of the pathogenesis and progression of MS and to address the unmet medical needs in MS, particularly progressive forms of the disease. Initially the collaboration will focus on projects that explore strategies to address neurodegeneration, a hallmark of progressive MS, and novel technologies to better understand the pathology of the disease. The collaboration will be led by a joint steering committee comprised of Genzyme and Cleveland Clinic researchers and span a minimum of 5 years.
Financial terms:
Latest news:
